FDA & Government News
Feature

MHRA Approval for First UK-made mRNA Vaccine

Moderna receives MHRA approval for updated COVID-19 vaccine targeting SARS-CoV-2 variant LP.8.1

  • By

  • February 27, 2026

  • 2 min

Share

  • 1

    Moderna's Spikevax® vaccine targets the LP.8.1 variant.

  • 2

    MHRA has authorized the vaccine for ages six months and older.

  • 3

    Vaccines will be supplied from Harwell, Oxfordshire.

  • 4

    The rollout is part of the 2026 NHS COVID-19 vaccination campaign.

  • 5

    The vaccine demonstrates UK competence in on-shoring vaccine production.

  • 6

    WHO recommended updates for 2026 vaccination campaigns.

  • 7

    Approval gained from multiple global regulators, including FDA and EMA.

Original Source(s)

MHRA Approval for First UK-made mRNA Vaccine

Moderna receives MHRA approval for updated COVID-19 vaccine targeting SARS-CoV-2 variant LP.8.1

  • February 27, 2026

  • 2 min

Related Content

Leukemia Case Prompts Broader Review

Researchers assess hematologic malignancies temporally associated with mRNA COVID-19 vaccination.

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.

When Obesity Meets Infection Risk

Researchers analyze data from Finnish cohorts and the UK Biobank to examine how body mass index relates to severe infections and their global burden.